Therapeutics

Latest Innovations

Biosynthesis of Lantibiotics: In vitro semi-synthetic production methods for generation of industrial antibiotic, Lacticin 481

 

This invention allows the engineering of semi-synthetic lantibiotics to a much larger extent than using typically practiced in vivo methods. The method is the...

Powerful Biphosophonates for Treatment of Cancer, Bone Loss, and Infectious Disease

 

Although there are already a few existing compounds for use in the treatment of bone diseases, these new compounds may have efficacy exceeding that of current...

Compounds That Selectively Induce Cancerous Cell Death in the G1 Phase of the Cell Cycle

 

Malignant melanoma is a cancer that is refractory to current chemotherapeutic treatments. The average survival time for patients is 6 months. This coupled with the...

New Drugs for Malarial and Bacterial Infections

 

New anti-infectives are required now more than ever as resistance to existing drugs increases in prevalence. Enzymes unique to bacteria or parasites are potential...

Gene Cluster Capable of Enabling the Biosynthesis of the Antimicrobial Compound, Rhizocticin In Bacillus subtilis

 

Phosphonic and phosphinic acids are bioreactive compounds that have been used as antibiotics, antifungal agents, antimalarial drugs, and herbicides. Rhizocticins...

Genes for the Biosynthesis of Plantazolicin, a Molecule Effective in Killing Bacillus Anthracis

 

Anthrax disease, caused the by the bacterium Bacillus anthracis, is a major bioterrorism threat. Currently, B. anthracis infections are treated with various broad-...

Antibacterial Drug Targeting Isoprenoid Biosynthesis

 

Researchers at the University of Illinois and the University of California at San Diego have developed a variety of potential inhibitors of Isoprenoid biosynthesis...

Compounds for the Treatment of Fluoquinolone resistant infections

 

Researchers from the University of Illinois have synthesized a variety of compounds with strong activity toward fluoroquinolone resistant bacteria. These compounds...

Therapeutic Agents for Treatment of Myotonic Dystrophy

 

Dr. Zimmerman's lab has developed a series of bioactive compounds for the treatment of myotonic dystrophy. The compounds disrupt the MBNL-(CUG) foci in vivo and...

Pharmaceutical Compounds and Pathways from Actinobacteria

 

Dr. Metcalf and Dr. van der Donk from the University of Illinois have discovered 12 novel phosphonate natural products as well as the genes responsible for the...

Pages